HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

Objectives. The response to HER2-targeted neoadjuvant chemotherapy (NAC) in HER2-positive (+) breast cancer can be quantified using residual cancer burden (RCB) pathologic evaluation to predict relapse free/overall survival. However, more information is needed to characterize the relationship betwee...

Full description

Saved in:
Bibliographic Details
Main Authors: Tamera J. Lillemoe, Mara Rendi, Michaela L. Tsai, Monica Knaack, Rina Yarosh, Erin Grimm, Barbara Susnik, Janet Krueger, Susan Olet, Karen K. Swenson
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:International Journal of Breast Cancer
Online Access:http://dx.doi.org/10.1155/2021/6684629
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items